AlphaGrep UK
LGND icon

AlphaGrep UK’s Ligand Pharmaceuticals LGND Stock Holding History

AlphaGrep UK’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$394K Buy
+1,262
New +$373K 0.12% 366

Other funds holding LGND

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

AlphaGrep UK's LGND Position: Q3 2026 in Review

AlphaGrep UK opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2026: 1,262 shares worth $394K. The stake represents 0.12% of the portfolio and ranks #366 among its holdings.

348 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • AlphaGrep UK held 1,262 shares of Ligand Pharmaceuticals worth $394K as of Q3 2026.
  • Ligand Pharmaceuticals was a new AlphaGrep UK position in Q3 2026.
  • Ligand Pharmaceuticals made up 0.12% of AlphaGrep UK's portfolio in Q3 2026, its #366 holding.
  • 348 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.